Will Roivant Sciences stock go up?

According to Danelfin AI, Roivant Sciences has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (47.23%) is -3.58% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Roivant Sciences stock?

The Roivant Sciences target price is $40.16 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Roivant Sciences stock right now?

Roivant Sciences has today a Sell rating (AI Score 3/10), according to Danelfin AI. Its probability of beating the market in 3 months (47.23%) is -3.58% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Roivant Sciences stock is a good buy .

Is Roivant Sciences undervalued right now?

Based on analysts, the average price target upside for Roivant Sciences is +14.59% (1Y). According to Danelfin AI, Roivant Sciences has today an AI Score of 3/10 (Sell Rating).

What was the price range of Roivant Sciences stock over the past 12 months?

The Roivant Sciences stock price range over the past 12 months has been $10.74 - $35.39.

What is going on with Roivant Sciences stock in the last 3 months?

The Roivant Sciences stock performance in the last quarter has been +26.53%.

Does Roivant Sciences offer dividend payments?

No, Roivant Sciences does not currently pay dividends.

What is the current market capitalization of Roivant Sciences?

Roivant Sciences's market cap is $25.2B, as of 2026-07-02 08:00.

When is the next ROIV earnings report date?

ROIV will publish its next earnings report on 2026-05-20.

Roivant Sciences Ltd (ROIV) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

ROIV AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Volatility+0.68%
How much the stock price tends to fluctuate

Momentum-2.61%
Direction and strength of recent price movements
Sentiment-1.26%
How analysts and the market view the stock
Valuation-0.39%
How the stock is priced relative to its fundamentals

ROIV probability advantage of beating the market (3M):

-3.58%

AI Score

Sell

Roivant Sciences (ROIV) has an AI Score of 3/10 (Sell) because, according to an overall analysis, it has a probability advantage of -3.58% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of ROIV (47.23%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
ROIV probability advantage of beating the market (3M)-3.58%
ROIV probability of beating the market (3M)47.23%

ROIV probability advantage of beating the market (3M): -3.58%

The AI-powered overall analysis of Roivant Sciences (ROIV) is based on the 23 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of ROIV:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Technical	Chart Pattern (120d)	figure_122	N/A	-1.76%
Sentiment	Industry (GICS)	Biotechnology	N/A	-1.46%
Sentiment	Country	United Kingdom of Great Britain and Northern Ireland	N/A	+1.13%
Technical	Chart Pattern (252d)	figure_59	N/A	+1.06%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.04%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	-0.97%
Technical	Maximum Volatility	4.39%		+0.51%
Technical	Chart Pattern (180d)	figure_53	N/A	-0.48%
Technical	Chart Pattern (504d)	figure_42	N/A	-0.46%
Technical	Technicals Impact (Long Tail)	-	N/A	+0.40%
Technical	Upgrade to unlock			-0.39%
Sentiment	Upgrade to unlock			+0.39%
Sentiment	Upgrade to unlock			-0.36%
Technical	Upgrade to unlock			-0.32%
Sentiment	Upgrade to unlock			-0.29%

Rest of Alpha Signals: -0.14%

ROIV probability advantage of beating the market (3M)Total:-3.58%
ROIV AI Score

Significant changes Vs previous day

ROIV Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$35.05
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

ROIV Proven Sell Signal & Price Forecast

This is the price chart for ROIV from January 2, 2026 until today. The chart indicates, in red, the 41 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

ROIV Average Past Performance & Loss Rate

Three months after its 609 Sell signals since July 2026, ROIV had an average performance of xxxxxx and a xxxxxx Loss rate (negative performance).

609 Past ROIV Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+47.89%
Average Alpha				+38.14%
Loss Rate (% Negative Perf.)				22.61%
% Negative Alpha				39.05%

ROIV Frequently Asked Questions

Will Roivant Sciences stock go up?
According to Danelfin AI, Roivant Sciences has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (47.23%) is -3.58% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Roivant Sciences stock?
Is it a good time to buy, sell, or hold Roivant Sciences stock right now?
Is Roivant Sciences undervalued right now?
What was the price range of Roivant Sciences stock over the past 12 months?
What is going on with Roivant Sciences stock in the last 3 months?
Does Roivant Sciences offer dividend payments?
What is the current market capitalization of Roivant Sciences?
When is the next ROIV earnings report date?

Roivant Sciences Ltd Company Profile

Based in London, UK and founded in 2014, Roivant Sciences Ltd. is a biopharmaceutical entity at the commercial stage, specializing in the research, development, and distribution of treatments for conditions related to immunology and inflammation. The company employs an innovative model termed as "Vants" to springboard its medicinal and technological discoveries into viable markets. This approach primarily caters to companies operating within the biopharmaceutical industry, start-ups focused on health technology, and enterprises in their discovery phase.

One of its remarkable drug innovations includes VTAMA - a transformative topical solution crafted for addressing skin conditions of psoriasis and atopic dermatitis. Other pioneering developments encompass batoclimab and IMVT-1402 – fully humanized monoclonal antibody therapies targeting neonatal Fc receptors for diverse IgG-mediated autoimmune indications across multiple patients' groups.

Additionally, RVT-3101 has been developed which is an anti-TL1A antibody offering promising treatment options for complex gastrointestinal ailments such as Crohn's disease and ulcerative colitis. This portfolio reflects Roivant’s commitment not only to addressing present-day health challenges but also projecting towards future patient needs through transformational therapies.

Sector:
Country:United Kingdom
Industry:
Address:7Th Floor, 50 Broadway, London
Employees:750
Website:roivant.com

Pros

Diversified drug pipeline across therapeutic areas

Multiple monetization pathways for drug assets

Asset-centric drug development model efficiency

Expertise in drug asset identification and development

Centralized capital access for subsidiary ventures

Cons

High capital requirements for clinical development

Binary outcomes inherent in drug trial phases

Stringent and unpredictable regulatory approval processes

Reliance on external drug candidate sourcing

Operational complexity from numerous subsidiary entities

Company	AI Score	Compare
IMVTImmunovant Inc
BMYBristol-Myers Squibb Co
AVBPArriVent BioPharma Inc
RIGLRigel Pharmaceuticals Inc

Company	AI Score	Compare
IMVTImmunovant Inc
BMYBristol-Myers Squibb Co
AVBPArriVent BioPharma Inc
RIGLRigel Pharmaceuticals Inc

ROIV Stock AI Analysis